Boston Scientific Corporation (BSX)
Health Care2 articles
Price chart
Boston Scientific Corporation (BSX) overview
Boston Scientific makes medical devices for cardiology and other specialties. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Boston Scientific Corporation trades on the NYSE under the ticker symbol BSX. As of the most recent market data, the stock was priced around $44.03, down 1.32% on the session, giving Boston Scientific Corporation a market capitalization of roughly $65.44B.
Over the past 52 weeks, BSX has traded between $42.20 and $109.50. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 18.7, a common gauge of how richly the market prices the company's earnings.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch BSX
As one of the larger companies in the Health Care sector, Boston Scientific Corporation is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch BSX for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest BSX news
Boston Scientific (BSX) Price Target Cut to $64 by Truist
Truist has decreased its price target for Boston Scientific Corp. (BSX) from $85 to $64 while maintaining a Buy rating. This revision comes after management indicated slowing growth in the U.S. market for the Watchman device. Goldman Sachs also cut its target price for BSX from $81 to $71, while still offering a Buy rating, noting expected revenue growth of at least 7% and a double-digit increase in EPS. The adjustments reflect analysts' concerns over the product's performance but confidence in BSX's broader financial profile.
Read More: Boston Scientific (BSX) Price Target Cut to $64 by Truist
Boston Scientific (BSX) Price Target Cut by Jefferies on Growth Outlook
Jefferies has lowered the price target for Boston Scientific (BSX) amid concerns over its growth outlook. Specific figures on the new price target or changes in revenue estimates were not disclosed in the report. This adjustment may influence investor sentiment and trading volumes as market participants evaluate the implications for BSX. Tracking the company's performance and comparing it with sector forecasts will be essential for identifying potential market movements.
Read More: Boston Scientific (BSX) Price Target Cut by Jefferies on Growth OutlookMore Health Care stocks
Frequently asked questions
Is Boston Scientific Corporation in the S&P 500?
Yes. Boston Scientific Corporation (BSX) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is BSX in?
Boston Scientific Corporation is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest BSX news?
This page collects recent Boston Scientific Corporation (BSX) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Boston Scientific Corporation's stock price?
As of the most recent market data, Boston Scientific Corporation (BSX) traded at approximately $44.03. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Boston Scientific Corporation's market cap?
Boston Scientific Corporation has a market capitalization of roughly $65.44B, based on its most recent share price and shares outstanding.
What is BSX's P/E ratio?
BSX trades at a trailing price-to-earnings ratio of about 18.7. The P/E ratio compares a company's share price to its earnings per share.